JP2018509143A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509143A5
JP2018509143A5 JP2017545273A JP2017545273A JP2018509143A5 JP 2018509143 A5 JP2018509143 A5 JP 2018509143A5 JP 2017545273 A JP2017545273 A JP 2017545273A JP 2017545273 A JP2017545273 A JP 2017545273A JP 2018509143 A5 JP2018509143 A5 JP 2018509143A5
Authority
JP
Japan
Prior art keywords
seq
formula
alkyl
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017545273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020127 external-priority patent/WO2016138534A2/en
Publication of JP2018509143A publication Critical patent/JP2018509143A/ja
Publication of JP2018509143A5 publication Critical patent/JP2018509143A5/ja
Priority to JP2021114792A priority Critical patent/JP2021166543A/ja
Priority to JP2023115841A priority patent/JP2023129494A/ja
Priority to JP2024060083A priority patent/JP2024074908A/ja
Ceased legal-status Critical Current

Links

JP2017545273A 2015-02-27 2016-02-29 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ Ceased JP2018509143A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021114792A JP2021166543A (ja) 2015-02-27 2021-07-12 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2023115841A JP2023129494A (ja) 2015-02-27 2023-07-14 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2024060083A JP2024074908A (ja) 2015-02-27 2024-04-03 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562126346P 2015-02-27 2015-02-27
US62/126,346 2015-02-27
US201562234263P 2015-09-29 2015-09-29
US62/234,263 2015-09-29
US201662300635P 2016-02-26 2016-02-26
US62/300,635 2016-02-26
PCT/US2016/020127 WO2016138534A2 (en) 2015-02-27 2016-02-29 Antisense-induced exon2 inclusion in acid alpha-glucosidase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021114792A Division JP2021166543A (ja) 2015-02-27 2021-07-12 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ

Publications (2)

Publication Number Publication Date
JP2018509143A JP2018509143A (ja) 2018-04-05
JP2018509143A5 true JP2018509143A5 (enExample) 2019-04-11

Family

ID=56789314

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017545273A Ceased JP2018509143A (ja) 2015-02-27 2016-02-29 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2021114792A Pending JP2021166543A (ja) 2015-02-27 2021-07-12 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2023115841A Pending JP2023129494A (ja) 2015-02-27 2023-07-14 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2024060083A Pending JP2024074908A (ja) 2015-02-27 2024-04-03 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021114792A Pending JP2021166543A (ja) 2015-02-27 2021-07-12 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2023115841A Pending JP2023129494A (ja) 2015-02-27 2023-07-14 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ
JP2024060083A Pending JP2024074908A (ja) 2015-02-27 2024-04-03 酸性アルファ-グルコシダーゼにおけるアンチセンスに誘導されるエクソン2の組入れ

Country Status (12)

Country Link
US (2) US20180216111A1 (enExample)
EP (1) EP3262056A4 (enExample)
JP (4) JP2018509143A (enExample)
AU (2) AU2016224976A1 (enExample)
BR (1) BR112017018383B1 (enExample)
CA (1) CA2977528A1 (enExample)
HK (1) HK1249106A1 (enExample)
IL (2) IL254112B (enExample)
MA (1) MA41759A (enExample)
MX (2) MX2017011004A (enExample)
TW (2) TW201702378A (enExample)
WO (1) WO2016138534A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105793422B (zh) 2013-09-05 2020-03-03 萨罗塔治疗公司(美国) 酸性α-葡糖苷酶中反义诱导的外显子2纳入
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
EP3201339A4 (en) 2014-10-03 2018-09-19 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
NZ737757A (en) 2015-05-19 2023-07-28 Sarepta Therapeutics Inc Peptide oligonucleotide conjugates
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
US20190030176A1 (en) 2015-12-15 2019-01-31 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP3445405A4 (en) * 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERS AND METHOD FOR USE THEREOF TO TREAT DISEASES RELATING TO THE ACID ALPHA GLUCOSIDASE GENE
NL2017294B1 (en) * 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) * 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
SI3673080T1 (sl) 2017-08-25 2024-03-29 Stoke Therapeutics, Inc. Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
WO2019209764A2 (en) * 2018-04-26 2019-10-31 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
BR112020022512A2 (pt) 2018-05-04 2021-05-04 Stoke Therapeutics, Inc. métodos e composições para tratamento de doença de armazenamento de éster de colesteril
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
CA3153902A1 (en) 2019-10-16 2021-04-22 Pardis SABETI Engineered muscle targeting compositions
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
WO2023283629A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
KR20240070615A (ko) * 2021-09-30 2024-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 하나 이상의 비염기성 유닛을 갖는 안티센스 올리고뉴클레오티드
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
WO2024016003A2 (en) 2022-07-14 2024-01-18 The Broad Institute, Inc. Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344302T3 (es) * 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2576574A2 (en) * 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
KR102183273B1 (ko) * 2011-05-05 2020-11-27 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CN108864192A (zh) * 2011-11-18 2018-11-23 萨勒普塔医疗公司 功能改性的寡核苷酸及其亚单元
NZ775701A (en) * 2013-03-14 2022-08-26 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
CN105793422B (zh) * 2013-09-05 2020-03-03 萨罗塔治疗公司(美国) 酸性α-葡糖苷酶中反义诱导的外显子2纳入
JP6901966B2 (ja) * 2014-05-16 2021-07-14 オレゴン ステート ユニバーシティ アンチセンス抗菌化合物および方法
EP3155100B1 (en) * 2014-06-10 2021-12-22 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease

Similar Documents

Publication Publication Date Title
JP2018509143A5 (enExample)
JP2019514426A5 (enExample)
US12414961B2 (en) Substituted nucleosides and nucleotides for treating viral infections
JP2016153410A5 (enExample)
JP2019521139A5 (enExample)
AU2024219862A1 (en) 4’-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2020503009A5 (enExample)
JP2019512478A5 (enExample)
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
JP2017515901A5 (enExample)
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
JP2018528261A5 (enExample)
JP2010527913A5 (enExample)
JP2017536344A5 (enExample)
JP2015512946A5 (enExample)
JP2016505586A5 (enExample)
JP2014521688A5 (enExample)
JP2017536395A5 (enExample)
JP2013172743A5 (enExample)
JP2020525502A5 (enExample)
JP2009541288A5 (enExample)
JP2019507111A5 (enExample)
JP2020514299A5 (enExample)
JP2018521056A5 (enExample)
JP2015520178A5 (enExample)